---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-026995"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T18:07:19.387952+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma Q4 2022 product revenue $8.8M, net loss $42.5M; BBS launch >200 scripts

## Summary
- Product revenue $8.8M Q4 2022, $16.9M FY; net loss $42.5M ($0.75/sh) Q4, $181.1M ($3.47/sh) FY.
- IMCIVREE for BBS: >200 new scripts from >125 physicians, >100 reimbursement approvals since FDA approval June 2022.
- Acquired Xinvento B.V. for congenital hyperinsulinism; founder Claudine van der Sande joins as VP, Head of CHI Program.
- Initiated pivotal Phase 3 trial for setmelanotide in acquired hypothalamic obesity; patient screening underway.
- FY 2023 non-GAAP operating expense guidance $200M-$220M.

## SEC filing metadata
- accession: 0001104659-23-026995
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465923026995/0001104659-23-026995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465923026995/tm237866d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-026995
- JSON: https://secwatch.observer/filing/0001104659-23-026995.json
- Plain text: https://secwatch.observer/filing/0001104659-23-026995.txt

## Key facts
- Earnings Releases
  RHYTHM PHARMACEUTICALS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $8.8 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $8.8 million
  - Result: reported results
  source text: • Revenue: Product revenue, net relating to global sales of IMCIVREE was $8.8 million for the fourth quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465923026995/0001104659-23-026995-index.htm
- Earnings Releases
  RHYTHM PHARMACEUTICALS, INC. reported the year ended December 31, 2022 results: revenue $16.9 million.
  - Period: the year ended December 31, 2022
  - Revenue: $16.9 million
  - Result: reported results
  source text: as $8.8 million for the fourth quarter of 2022 and $16.9 million for the year ended Decem
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649904/000110465923026995/0001104659-23-026995-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.